

VIVALIS SIGNS A NEW COMMERCIAL LICENSE FOR THE EB66[®] CELL LINE WITH KYOTO BIKEN LABORATORIES

Nantes & Lyon (France) and Kyoto (Japan) – June 21st, 2011: VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today that KYOTO BIKEN LABORATORIES, one of the largest animal vaccine manufacturers in Japan, entered into a commercial license agreement with VIVALIS to produce a veterinary vaccine in VIVALIS' EB66[®] duck embryonic stem cell line.

Yoichi Kakuta C.O.O of KYOTO BIKEN stated, *"In our continued commitment to deliver safer and higher quality products to our clients, we are very happy to expand our use of the EB66[®] cell line for a next-generation veterinary vaccine."*

Franck Grimaud, C.E.O. and Majid Mehtali, C.S.O., co-managers of VIVALIS, commented, *"We are very pleased to have KYOTO BIKEN expand their relationship with VIVALIS into a new commercial agreement within the animal vaccine field. With about 30 licenses on going, and three new licenses signed since the beginning of 2011, this further confirms that the majority of our clients who enter into an evaluation license are more than satisfied with the robustness, efficiency, and regulatory compliance of our EB66[®] cell line by their extension into commercial use."*

VIVALIS will receive upfront and development milestone payments as well as royalty payments associated with product sales.

**Next financial press release: 2011 first-half sales, 21 July 2011
after NYSE Euronext market closing**

About VIVALIS (www.vivalis.com)

VIVALIS (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:

EB66[®] Cell Line

VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66[®] cell line based vaccines are currently in clinical trials in USA and in Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

VIVALIScreen™ Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies is now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees' net sales.

3D-Screen: Drug Discovery Platform

VIVALIS performs discovery and development, up to pre-clinical evaluation, of original small chemical molecules identified with its proprietary platform, 3D-SCREEN. This unique screening platform is designed to identify original molecules that alter the three-dimensional structure of a target protein, thus modulating its biological function through an innovative mode of action. VIVALIS is building a portfolio of proprietary new chemical entities for the treatment of hepatitis-C virus infection. VIVALIS also proposes, on a fee for service basis, to develop ready to use customized 3D-Screen HTS assays directed against client's target protein of interest.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud group (ca. 1,500 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Intervet, SAFB Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.

VIVALIS

Listed on Euronext Paris – Compartment B of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including the risk factors described in the company's registration document (document de référence), changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Steve Grobet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr